Sionna Therapeutics, INC Form 4 insider transactions

Sionna Therapeutics Director Peter A. Thompson reported a sale of 85,918 shares of common stock on July 7, 2026, executed under a Rule 10b5-1 trading plan.

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC have reported the sale of 85,918 shares of Sionna Therapeutics, Inc. common stock.

Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics, Inc., sold 10,250 shares of common stock for approximately $43.60 per share under a pre-arranged 10b5-1 trading plan.

Sionna Therapeutics Director Peter A. Thompson reported a sale of 115,844 shares of common stock on June 30, 2026, executed under a Rule 10b5-1 trading plan.

OrbiMed Advisors LLC, a significant holder, has reported the sale of 115,844 shares of Sionna Therapeutics, Inc. common stock on June 30, 2026, executed under a Rule 10b5-1(c) trading plan.

Laurie Stelzer, a Director at Sionna Therapeutics, Inc., was granted 17,340 non-qualified stock options with an exercise price of $36.73.

Joanne L. Viney, a Director at Sionna Therapeutics, Inc., acquired 17,340 stock options with an exercise price of $36.73.

Peter A. Thompson, a Director at Sionna Therapeutics, Inc., reported the acquisition of stock options on June 17, 2026, as detailed in a Form 4 filing.

RA Capital Management, through various entities, has reported beneficial ownership of stock options and common stock in Sionna Therapeutics, Inc., indicating a significant investment and board representation.

Marcella K. Ruddy, a Director at Sionna Therapeutics, Inc., acquired 17,340 non-qualified stock options with an exercise price of $36.73.

Director Joshua Resnick of Sionna Therapeutics, Inc. has reported the acquisition of a stock option, detailing its terms and beneficial ownership arrangements.

Harold Edward Fleming, a Director at Sionna Therapeutics, Inc., reported the acquisition of a stock option grant on June 17, 2026.

Paul J. Clancy, a Director at Sionna Therapeutics, Inc., acquired 17,340 non-qualified stock options with an exercise price of $36.73, vesting on June 17, 2027.

Sionna Therapeutics, Inc. director Bruce Booth has reported the acquisition of a non-qualified stock option to purchase 17,340 shares of common stock.

Director Peter A. Thompson reported the sale of 101 shares of Sionna Therapeutics, Inc. common stock via a 10b5-1 trading plan.

OrbiMed Advisors LLC reported the sale of 101 shares of Sionna Therapeutics, Inc. common stock via a Rule 10b5-1 trading plan.

Director Peter A. Thompson reported the sale of 292,952 shares of Sionna Therapeutics, Inc. common stock via a 10b5-1 trading plan.

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC reported the sale of 292,952 shares of Sionna Therapeutics, Inc. via a 10b5-1 trading plan.

Director Peter A. Thompson reported the sale of 55,345 shares of Sionna Therapeutics common stock via a 10b5-1 trading plan.

OrbiMed Advisors LLC reported the sale of 55,345 shares of Sionna Therapeutics, Inc. via a Rule 10b5-1 trading plan.

Director Peter A. Thompson sold 510,583 shares of Sionna Therapeutics, Inc. (SION) via a pre-arranged 10b5-1 trading plan.

OrbiMed Advisors LLC reported the sale of 510,583 shares of Sionna Therapeutics, Inc. via a 10b5-1 trading plan.

Sionna Therapeutics' Chief Legal Officer, Jennifer Fitzpatrick, exercised stock options and subsequently sold 10,250 shares for a significant gain under a pre-arranged trading plan.

Sionna Therapeutics Director Peter A. Thompson reported sales of common stock totaling 30,953 shares in early February 2026.

OrbiMed Advisors, a 10% owner and director, reported the sale of Sionna Therapeutics common stock totaling 30,953 shares across two transactions in early February 2026.

TPG GP A, a 10% owner and director of Sionna Therapeutics, Inc., reported the sale of 250,000 shares of common stock at $40 per share.

Sionna Therapeutics' Chief Medical Officer, Charlotte McKee, was granted 155,700 non-qualified stock options with an exercise price of $39.21.

Sionna Therapeutics' Chief Legal Officer, Jennifer Fitzpatrick, was granted 103,140 non-qualified stock options with an exercise price of $39.21, vesting monthly over four years.

Sionna Therapeutics' President and CEO, Michael Cloonan, was granted 436,100 non-qualified stock options with an exercise price of $39.21.

Sionna Therapeutics' Chief Business Officer, Caroline Stark Beer, was granted 139,340 non-qualified stock options with an exercise price of $39.21.